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OBJECTIVE: Cost-effectiveness, -utility and -benefit
analyses have made a substantial impact on heath care.
Current approaches are methodologically coherent and
provide a basis for improved resource allocation. As has
been noted before, they are based on expected (average)
outcome and do not take into account patients’ risk pref-
erences, which are important aspects of clinical decision-
making. From a patient’s perspective, a treatment associ-
ated with a lower level of expected clinical benefit may be
preferred if it has better worst-case scenario than a treat-
ment with higher expected (average) benefit. We analyze
decision-scientific methodology in order to incorporate
risk preferences into the framework of outcome and util-
ity studies.
METHODS: Concepts of risk preferences in decision-
making from economics and management science are de-
scribed, and their applicability to a clinical context is
tested using a decision tree model. Methods analyzed in-
clude the Bayes-Principle of expected value (m-principle),
the m-s-principle, risk restriction with given outcome and
the Bernoulli-Principle. The absence of risk preferences in
the QALY (quality adjusted life years) and HYE (healthy
years equivalent) concepts is shown mathematically.
RESULTS: Current methodological concepts used in out-
comes research do not adequately incorporate patients’
risk preferences. On the basis of a modified standard
gamble approach a method of obtaining risk preferences
for given treatment outcome is developed. It leads to the
determination of relative marginal utilities and may be
used in choosing health-care interventions by considering
relative marginal costs.
CONCLUSION: Patients’ risk preferences should be taken
into account in outcome and utility analyses involving sub-
stantial risks. The approach proposed here may improve
the empirical estimation of patients’ preferences and the
quality of resource allocation in health care.
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OBJECTIVE: Support for the reliability and validity of
the Medical Outcomes Study (MOS) Sleep Scale was pro-
vided in the MOS sample of 3445 individuals with
chronic illness. We sought to extend this work by evalu-
ating the psychometric properties of the MOS-Sleep Scale
in the US general population.
METHODS: The MOS-Sleep Scale is a 12-item, self-re-
ported survey that yields six subscales: sleep disturbance,
snoring, awaken short of breath or with headache, quan-
tity of sleep, sleep adequacy, and somnolence as well as a
nine-item sleep problem index. The subscales and prob-
lem index are scored on a 0 to 100 range, with higher
scores indicating more of the domain being measured.
We administered the MOS measure by telephone to a na-
tionally representative sample of 1011 US adults aged 18
and older in January 2001.
RESULTS: The average age of the sample was 46; 51%
were female and 74% were white. Internal consistency
reliability estimates for the MOS-Sleep scales tended to
be adequate: sleep disturbance (4 items, alpha  0.80);
sleep adequacy (2 items, alpha  0.82); sleep somnolence
(3 items, alpha  0.63); and nine-item sleep problems in-
dex II (alpha  0.83). Adjusting for age and gender,
MOS patients reported significantly more quantity of
sleep (t  3.27, P  .002), but significantly worse sleep
disturbance (t  5.08, P  .001), snoring (t  2.16, P 
.05), shortness of breath (t  4.59, P  .001), sleep ade-
quacy (t  2.39, P  .05), somnolence (t  5.10, P 
.001), and sleep problems (t  3.27, P  .002) than the
general US population.
CONCLUSIONS: The MOS-Sleep Scale was found to
have good internal consistency reliability and to discrimi-
nate between patients with chronic illness and the US
general population. Further work is needed to compare
the MOS-Sleep Scale results with objective measures of
sleep such as polysomnography.
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OBJECTIVE: To analyze health-related quality of life
among people with sleeping problems from an epidemio-
logical perspective.
METHOD: A cross-sectional survey on a sample aged
between 20 and 84 years in the county of Uppland, Swe-
den yielded a response in 5404 patients (68%). A recall
period of two weeks was used for sleeping problems and
use of sleeping medication. The SF-36, used to measure
HRQoL, covers eight domains of health: physical func-
tion (PF); role limitation because of physical health (RP);
bodily pain (BP); general health perception (GH); vitality
(VT); social functioning (SF); role limitation because of
emotional health problem (RE), and mental health (MH).
Linear regression analysis was employed for the multi-
variate analyses.
RESULTS: In all, 20.3% of the population reported
sleeping problems. Sixteen percent had experienced sleep-
ing problems but had not used sleeping medication while
4.3% had used medication. The prevalence of sleeping
problems was of the same magnitude between the ages of
20 to 74 years (around 20%) but higher among those
aged 75 to 84 years (29.5%). Sleeping problems were
more prevalent among women (23.8%) than men (16.1%).
The use of sleeping medication increased by age. Among
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persons aged 20 to 34 years, 1.0% had used sleeping
medication and among those aged 75 to 84 years 16.1%
did. Use of sleeping medication was more common among
women (5.3%) compared to men (3.0%). Individuals with
sleeping problems scored significantly lower (p  .05) than
those without sleeping problems on all of the eight do-
mains in SF-36  RE  20.3; VT  19.3; MH  16.8;
GH  16.2; SF  15.6; RP  15.1; BP  13.4 and PF 
7.9. Among individuals with sleeping problems, those us-
ing sleeping medication scored lower on seven domains
of the SF-36  RE  10.5; MH  10.4; SF  8.8; GH 
8.1; BP  7.8; VT  6.1 and PF  5.8.
CONCLUSION: Sleeping problems are common in the
population and lead to a significantly decreased quality
of life among affected individuals.
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OBJECTIVE: Depression is a common recurrent disease.
Usually, each successive episode of depression is more
difficult to cure. The objective of this study is to assess
costs, methods of treatment, and outcomes of the first ep-
isode of depression compared to the second and subse-
quent episodes.
METHODS: Study was designed as a one-year prospec-
tive, natural observation. Psychiatrists who took part in
this trial recruited one patient with a first episode of de-
pression, one with a second episode after a period of re-
mission and one with a third or next episode after a pe-
riod of remission. During the study, carried out in 1999
with three months tolerance, data concerning treatment
methods, their outcomes, changes in health state, and
economic and social consequences of depression were
collected. A social perspective was applied. The capital
cost method was used for indirect costs.
RESULTS: Five hundred thirty two patients were in-
cluded, and 94% of them were followed to the end of the
study (one-year observation). The average direct medical
cost per patient with a first episode of depression was
2097 PLN (1 Euro  3.50 PLN), with a second was 2241
PLN and with a third and the following 3357 PLN. Di-
rect medical costs included: the cost of hospitalization
(49%); doctors consultations (29%); non-pharmacologi-
cal treatment (14%); pharmacological treatment (8%);
laboratory and diagnostic tests (1%). Indirect costs per
patient with a first episode reached 10,834 PLN, with a
second, 13,802 PLN, and with a third and following,
15,012 PLN. The distribution of indirect cost was as fol-
lows: sick leaves 40.5%, sickness pensions 59%, and sui-
cides 0.5%. Total costs in the three study groups were
12,931 PLN, 16,043 PLN and 18,369 PLN respectively.
CONCLUSIONS: Treatment of a third episode of de-
pression costs 60% more than the first episode. Direct
medical costs account for only 16% of total costs.
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OBJECTIVE: Schizophrenia is probably one of the most
costly mental-health illnesses in terms of its impact on the
society, on the health-care system and on patients and
their families. We aim to develop a framework for ana-
lyzing schizophrenia through the estimation of the costs
of illness as well as the costs of relapse in the manage-
ment of schizophrenia in a UK care setting.
METHODS: A model that utilizes a Markov structure was
elaborated in order to calculate the lifetime cost of illness
and the principal cost driver in schizophrenia, the cost of
relapse. The model included the main confounding factors
such as compliance, dropout, and treatment location,
which have been shown to be important in the literature
when constructing a model. The costs were estimated for a
10-year period as well as for the lifetime of a patient, and
consider all types of treatment structures in the UK.
RESULTS: The average 10-year cost of illness for a patient
in a UK treating environment was estimated at £ 66 600,
and the lifetime cost per patient at £ 98 510. As for the cost
of relapse of a schizophrenic patient, the 10-year cost was
£ 51 630 and the lifetime cost per patient was £ 75 890.
CONCLUSIONS: This model enables the identification
and the calculation of the main cost drivers in the treat-
ment of schizophrenia. This model can therefore be used
to evaluate the cost implication of treatment options and
policy choices, by generating budgetary provisions. Hence,
this model can help decision-makers in policy-making for
mental health-care organizations in the management of
schizophrenia.
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INDIRECT COSTS DUE TO BACK PAIN IN THE 
UNITED STATES
Mychaskiw MA, Thomas III J
Purdue University, West Lafayette, IN, USA
OBJECTIVE: Back pain is a leading cause of absence and
disability in the workplace. Costs associated with lost
productivity due to back pain are significant and may be
as high as the costs of medical care for this condition.
However, there has been limited study of the indirect
costs of back pain in the United States. The objective of
this study was to determine the indirect costs due to back
pain in the US population.
